Answer
Bullous pemphigoid has been reported in patients taking linagliptin, including 0.2% of linagliptin-treated patients versus none receiving placebo in CARMELINA, and linagliptin should be discontinued if bullous pemphigoid is suspected.
Sources for this answer
- Trajenta 5 mg film-coated tabletsBoehringer Ingelheim Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 18Document updated
Sources checked